Why You Buy Big Pharma If the Market Crashes
A new report from the global equity strategy team at Credit Suisse maintains that the best defensive sector now is large cap pharmaceuticals. Here are their top large cap pharmaceuticals to buy now.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 289Top Biotech Stocks for Cancer Cures From Cowen
ThinkstockThe conference season is starting to get into full swing, and for the top biotech stocks, that means an appearance at the American Society of Clinical Oncology yearly conference. Many of the top names…
Three Oversold Biotech Stocks That Could Have Gigantic Upside
ThinkstockThe biotech meltdown that started in late February was an indiscriminate killer. The top mega-cap sector leaders were shot down in flames along with small cap names that have yet to make a dime.…
Should Allergan Shareholders Be Worried?
Allergan has been a great company, and it can still be one in the future. The question is whether this greatness will be as an independent company or as a subsidiary of Valeant Pharmaceuticals.
Will the Last Interested Person in Dendreon Turn Out the Lights?
Dendreon is getting crushed, and the share price is down to levels not seen in a decade. The company's reported Provenge sales were again unimpressive. It feels like investor interest has died.
Cross-Border Premium Implications in Merck-Bayer Transaction
Merck has had its consumer products business on the market since the beginning of this year, and Tuesday it announced that it had sold the business to Germany-based Bayer for $14.2 billion.
VIVUS Blows Out Estimates, but Qsymia Units Drop Sequentially
ThinkstockVIVUS Inc. (NASDAQ: VVUS) is going to have to explain how its diet pill Qsymia had lower prescription volumes sequentially. If you just look at the revenue number, it looks massively higher at $36.7…
Pfizer Earnings Confirm Reasons for AstraZeneca Offer
Drug giant Pfizer reported better-than-expected first-quarter 2014 earnings before markets opened Monday morning, but revenues fell short. Shares traded lower in the premarket.
Can Endocyte Survive Its Cancer Drug Implosion?
Endocyte and Merck have terminated their joint late-stage study of an ovarian cancer treatment after the trials failed to show results. Endocyte expressed surprise at the recommendation to halt the trial.
AstraZeneca Declares Pfizer Bid ‘Inadequate’
British drug maker AstraZeneca once again rejected a takeover bid from U.S. pharmaceutical giant Pfizer, this one worth $106 billion (about £50 a share) in cash and stock.
Young People Enroll as Obamacare Enrollment Reaches Eight Million
thinkstockObamacare sign ups reached eight million, although the Obama administration put the figure higher because of 4.8 million sign ups for Medicaid and CHIP. The U.S. Department of Health and Human Services also disclosed that…
Why Teva Sees a Sell-the-News Reaction to Decent Earnings
Teva Pharmaceutical is finding a bit of a sell-the-news reaction to its first-quarter earnings report. The company said revenues rose 2% from a year ago and net income rose by 8%.
Mylan Falls Short on Revenues, Hints at Acquisition to Come
Mylan reported first-quarter 2014 results before markets opened Thursday. The generic drug maker reaffirmed its full-year EPS guidance and hinted at an acquisition by the end of the year.
States Where People Go to the Dentist
ThinkstockClean teeth are supposed to be good for heart health, and a way to avoid dentures and to avoid the drilling, which comes with cavities as well. Some people are more willing to go…
Salvation for Avanir in Patent Exclusivity
ThinkstockAvanir Pharmaceuticals, Inc. (NASDAQ: AVNR) is seeing a late day surge on Wednesday after news broke that the company has prevailed in a patent fight covering NUEDEXTA. This drug remains the only FDA-approved product…